The company's platform utilizes novel reagents to power efficient multiplexed assay workflows compatible with existing imaging instrumentation. This enables scientists and clinicians to translate biomolecular and cellular information into actionable insights, leading to advancements in the study of biology, health, and disease. Arvetas Biosciences aims to facilitate the development of precision diagnostics and treatments through their highly innovative multiplex labeling approach and proprietary imaging platform. Founded in 2020 and based in Irvine, California, Arvetas Biosciences is at the forefront of the next wave of multi-omics 3D tissue analysis.